PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC
NCT ID: NCT02777658
Last Updated: 2021-05-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
169 participants
OBSERVATIONAL
2016-05-26
2020-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients
NCT03171636
Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
NCT01081496
A Study of Prevalence of EGFR Mutations in Participants With NSCLC
NCT02695849
A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology
NCT01106781
A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors
NCT02674555
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Primary Study Cohort
Patients with prior confirmed EGFR mutation-positive locally advanced or advanced NSCLC (Non-Small Cell Lung Cancer) who have progressed on or after EGFR-TKI (Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitor) therapy
No interventions assigned to this group
Secondary Study Cohort
Patients diagnosed with de-novo (wild-type) EGFR T790M mutation-positive (alone or in combination with other mutations) locally advanced or advanced NSCLC
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult male or female subjects (according to age of majority/adulthood as defined by local regulations)
* Patients with prior confirmed EGFR mutation-positive (all mutations) locally advanced or advanced NSCLC - Patients who developed resistance to an EGFR-TKI due to any other phenotypic/histologic transformations (e.g., small-cell lung cancer, EMT) or other mutations (e.g., HER2, MET amplifications) at the index-date will be eligible for participation in this study as long as they have prior confirmed diagnosis of EGFR mutation-positive (all mutations) locally advanced or advanced NSCLC
* Patients who have progressed on or after EGFR-TKI therapy (i.e., gefitinib, erlotinib or afatinib) within the patient selection period
* Provision of written informed consent (patient consent should be within 6 weeks of NSCLC diagnosis, defined elsewhere as the Index Date)
* Adult male or female subjects (according to age of majority/adulthood as defined by local regulations)
* Patients diagnosed with de-novo EGFR T790M mutation-positive locally advanced or advanced NSCLC during the patient selection period. The de-novo T790M mutation can be alone or in combination with other mutations (e.g., L858R and T790M).
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
iOMEDICO AG, Freiburg, Germany
UNKNOWN
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Aschaffenburg, , Germany
Research Site
Augsburg, , Germany
Research Site
Bad Kreuznach, , Germany
Research Site
Ballenstedt, , Germany
Research Site
Bautzen, , Germany
Research Site
Berlin, , Germany
Research Site
Bochum, , Germany
Research Site
Bonn, , Germany
Research Site
Bottrop, , Germany
Research Site
Bremen, , Germany
Research Site
Celle, , Germany
Research Site
Cologne, , Germany
Research Site
Dresden, , Germany
Research Site
Düsseldorf, , Germany
Research Site
Erfurt, , Germany
Research Site
Esslingen am Neckar, , Germany
Research Site
Frankfurt (Oder), , Germany
Research Site
Freiburg i.Br., , Germany
Research Site
Freital, , Germany
Research Site
Fürth, , Germany
Research Site
Gauting, , Germany
Research Site
Georgsmarienhütte, , Germany
Research Site
Goslar, , Germany
Research Site
Göttingen, , Germany
Research Site
Greifenstein, , Germany
Research Site
Güstrow, , Germany
Research Site
Gütersloh, , Germany
Research Site
Halle, , Germany
Research Site
Hamburg, , Germany
Research Site
Hanover, , Germany
Research Site
Heidenheim, , Germany
Research Site
Herne, , Germany
Research Site
Hildesheim, , Germany
Research Site
Hof, , Germany
Research Site
Kaiserslautern, , Germany
Research Site
Karlsruhe, , Germany
Research Site
Kempten, , Germany
Research Site
Koblenz, , Germany
Research Site
Krefeld, , Germany
Research Site
Landshut, , Germany
Research Site
Lebach, , Germany
Research Site
Leipzig, , Germany
Research Site
Löwenstein, , Germany
Research Site
Ludwigsburg, , Germany
Research Site
Mainz, , Germany
Research Site
Mönchengladbach, , Germany
Research Site
Muehlheim A.d. Ruhr, , Germany
Research Site
München, , Germany
Research Site
Münnerstadt, , Germany
Research Site
Naunhof, , Germany
Research Site
Neustadt a.R., , Germany
Research Site
Nuremberg, , Germany
Research Site
Offenburg, , Germany
Research Site
Oldenburg, , Germany
Research Site
Osnabrück, , Germany
Research Site
Pirna, , Germany
Research Site
Porta Westfalica, , Germany
Research Site
Ratingen, , Germany
Research Site
Ravensburg, , Germany
Research Site
Rosenheim, , Germany
Research Site
Rostock, , Germany
Research Site
Schorndorf, , Germany
Research Site
Stolberg, , Germany
Research Site
Stuttgart, , Germany
Research Site
Twistringen, , Germany
Research Site
Völklingen, , Germany
Research Site
Wangen, , Germany
Research Site
Westerstede, , Germany
Research Site
Wiesbaden, , Germany
Research Site
Witten, , Germany
Research Site
Würselen, , Germany
Research Site
Würzburg, , Germany
Research Site
Zittau, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D5160R00005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.